Compare Medtronic PLC (MDT) vs Target Corporation (TGT) Price & Performance

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

Target (TGT) trades at $139.11, down 0.37% on the day, with a bullish technical outlook supported by moving averages and recent earnings beats. The stock shows solid fundamentals with a P/E of 18.44, P/S of 0.6, and ROE of 22.02%, while revenue remains stable around $106 billion. Positive sentiment is driven by improved traffic trends and merchandising updates noted by Jefferies on July 15, 2026.

Target presents a balanced opportunity with strong profitability and analyst support, though risks include competitive retail pressures and margin volatility. The consensus price target of $137 suggests limited upside, but consistent dividend payments and operational cash flow near $7.4 billion provide stability. Execution on merchandising initiatives will be key for sustained growth.